Sanjeev Kaul
Urology · Saginaw, MINPI 1447469242
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 28.6% of the total. Reporting peaked in 2019 at $11,580 and has fallen 94.0% since, to $695 in 2025.
Across 195 payments — averaging $104.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$6K
- Foundation Medicine, Inc.$4K
- Myriad Genetic Laboratories, Inc.$4K
- Boston Scientific$1K
- Procept Biorobotics Corporation$1K
- Dendreon Pharmaceuticals LLC$893
- plus $4K from 32 others
What the payments were for
- Consulting fees$8,48041%
- Speaking & faculty fees$3,70018%
- Travel & lodging$2,41812%
- Food & beverage$5,76528%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 6 | $5,839 |
| Foundation Medicine, Inc. | 4 | $3,945 |
| Myriad Genetic Laboratories, Inc. | 15 | $3,918 |
| Boston Scientific | 8 | $1,160 |
| Procept Biorobotics Corporation | 13 | $1,138 |
| Dendreon Pharmaceuticals LLC | 23 | $893 |
| Teleflex LLC | 9 | $411 |
| Smith+Nephew | 16 | $349 |
| AbbVie(2 entities) | 19 | $341 |
| Astellas Pharma US Inc | 12 | $332 |
| Intuitive Surgical | 4 | $314 |
| Olympus America Inc. | 10 | $309 |
| Baxter Healthcare | 4 | $203 |
| Sumitomo Pharma America, Inc. | 2 | $145 |
| Myovant Sciences Inc. | 2 | $143 |
| Blue Earth Diagnostics | 6 | $129 |
| Axonics, Inc. | 5 | $93 |
| 180 Medical, Inc. | 5 | $90 |
| Neotract Inc. | 1 | $73 |
| Pfizer | 4 | $59 |
| Tolmar Pharmaceuticals, Inc. | 3 | $53 |
| Coloplast | 3 | $46 |
| SRS Medical Systems, Inc. | 1 | $42 |
| AstraZeneca | 3 | $40 |
| Urogen Pharma, Inc. | 1 | $39 |
| Telix Pharmaceuticals | 1 | $39 |
| Laborie Medical Technologies Corp. | 2 | $38 |
| Angiodynamics, Inc. | 1 | $35 |
| Amgen | 2 | $35 |
| Johnson & Johnson | 2 | $35 |
| Endo USA, Inc. | 1 | $29 |
| Medtronic | 1 | $26 |
| Calyxo, Inc. | 1 | $23 |
| Conmed Corporation | 1 | $19 |
| Abbott | 1 | $18 |
| Cook Medical LLC | 1 | $17 |
| Merck | 1 | $16 |
| Bayer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONACT$3,945
- FOUNDATIONFOCUS$3,945
- FOUNDATIONONE CDX$3,945
- FOUNDATIONONE HEME$3,945
- FOUNDATIONONE$3,945
- Prolaris$3,265
- AQUABEAM SYSTEM$851
- PROVENGE$501
- AMS 700 CXR RTE KIT$480
- AMS$465
- BRACAnalysis CDx$350
- ORGOVYX$247
- UroLift$150
- Stravix$138
- Da Vinci Surgical System$136
- GENERAL MALE SUI$131
- TISSEEL$124
- AquaBeam Robotic System$111
- iTIND System$110
How this compares
$20,448 in reported general payments places this provider in the 85th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 69 | $45,555 |
| GemtesaVibegron | 30 | $18,951 |
| Mirabegron ErMirabegron | 23 | $10,099 |
| Tamsulosin Hcl | 485 | $6,523 |
| Tolterodine Tartrate ErTolterodine Tartrate | 103 | $5,513 |
| Potassium Citrate ErPotassium Citrate | 44 | $5,031 |
| Oxybutynin Chloride ErOxybutynin Chloride | 240 | $3,709 |
| Testosterone | 24 | $1,570 |
| Bicalutamide | 34 | $1,558 |
| Silodosin | 15 | $793 |
| Ciprofloxacin Hcl | 206 | $738 |
| Cephalexin | 101 | $513 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 19 | $444 |
| Finasteride | 35 | $374 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $332 | $45,55569 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $145 | $18,95130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 urology providers in Michigan.
Other urology in Saginaw
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- Kenneth KernenTroy$910K
- William JohnstonLivonia$675K
- Jason HafronWest Bloomfield$490K
- Khurshid GhaniAnn Arbor$413K
- Richard BennettRoyal Oak$361K
- Ryan NelsonUtica$296K
- Casey DauwAnn Arbor$188K
- Aram LoebDetroit$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.